Dasatinib Tablet Dyronib 70mg Tablet

Get a Price/Quote

MOQ : 10 Boxes

Dasatinib Tablet Dyronib 70mg Tablet Specification

Packaging Type
Box

Pacakaging (Quantity Per Box)
60 Tablets per box

Origin of Medicine
India

Life Span
24 months from manufacturing date

Salt Composition
Dasatinib 70 mg

Dosage Form
Film-coated tablet

Brand Name
Dyronib

Indication
Treatment of Philadelphia chromosome-positive leukemia

Drug Type
Prescription only anti-cancer drug

Ingredients
Dasatinib

Physical Form
Tablet

Function
Anticancer medication

Recommended For
Adults with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL)

Dosage
As prescribed by physician, commonly once daily

Dosage Guidelines
Take with or without food, swallow whole with water

Quantity
60 Tablets

Storage Instructions
Store below 30C, protect from moisture and light

Caution
To be sold by retail on the prescription of an oncologist only

Country of Approval
Approved in multiple countries including Canada, USA, UK, Australia, European Union

Therapeutic Class
Antineoplastic agent

Color
White to off-white

Route of Administration
Oral

Prescription/Non Prescription
Prescription

Dasatinib Tablet Dyronib 70mg Tablet Trade Information

Minimum Order Quantity
10 Boxes

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Boxes Per Month

Delivery Time
2-10 Days

Main Domestic Market
All India

Dasatinib Tablet Dyronib 70mg Tablet About

Dyronib 70mg Dasatinib Tablet stands as a meritorious antineoplastic agent, lauded for its efficacy in managing Philadelphia chromosome-positive leukemia. Highlighted by its status as a laureate product, this prescription-only, film-coated tablet provides an ephemeral yet potent therapeutic intervention, suitable for adult patients with CML or ALL. Scarce in its availability due to strict prescription guidelines, Dyronib brings best-in-class cancer-fighting capacity as approved across Canada, USA, UK, and European countries. Manufactured in India, this white to off-white tablet ensures reliable dosage, maintained potency, and robust stability within its 24-month life span.

Dyronib 70mg: Targeted Application & Clinical Advantages

The site of application for Dyronib Dasatinib 70mg Tablet is systemic, functioning as an oral antineoplastic agent for adults with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL). Its advantage lies in targeted treatment, prioritizing efficacy and safety in Philadelphia chromosome-positive cases. Used as a critical component of cancer therapy, Dyronib delivers a reliable oral route, supporting adherence and patient convenience. The tablet's formulation ensures optimal bioavailability and clinical result stability.

Sample Policy, Certifications, and Estimated Supply of Dyronib

Dyronib 70mg maintains a stringent sample policy, often reserved for institutional valuation and regulated by prescription protocols. The tablet is manufactured under recognized certifications, adhering to international standards. Supply ability is estimated in alignment with demand and prescriber expenditure, ensuring availability without surplus or scarcity. Every procurement undergoes expenditure assessment to conform to medical and regulatory requirements, optimizing distribution based on calculated usage and clinical forecast.

FAQ's of Dasatinib Tablet Dyronib 70mg Tablet:

Q: How should Dyronib 70mg Dasatinib Tablet be administered?

A: Dyronib 70mg Dasatinib Tablet should be taken once daily, as prescribed by a physician. Swallow the film-coated tablet whole with water, either with or without food, and avoid breaking or crushing the tablet.

Q: What is the primary benefit of using Dyronib Dasatinib 70mg Tablet?

A: The main benefit of Dyronib is its targeted action against Philadelphia chromosome-positive leukemias, offering a meritorious treatment option that is supported by international approvals for adult CML or ALL patients.

Q: When is the use of Dyronib indicated?

A: Dyronib is indicated for the treatment of adults diagnosed with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive, under the guidance of an oncologist.

Q: Where is Dyronib 70mg Tablet manufactured and approved?

A: Dyronib 70mg Tablet is manufactured in India and is approved for use in multiple countries, including Canada, the USA, the UK, Australia, and within the European Union.

Q: What precautions are necessary when storing Dyronib tablets?

A: Store Dyronib tablets below 30C, protecting them from moisture and light. Ensure the medicine remains in its original packaging to maintain efficacy and safety throughout its 24-month shelf life.

Tell us about your requirement